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Abstract  
This article provides a review of the epidemiological data on mumps in France since 1986. 
The results of 26 years of monitoring in general practice by the Sentinel network are analysed, 
such as hospitalisation data between 2004 and 2010, as well as mortality data between 2000 
and 2009. The annual incidence rate has plummeted between 1986 and 2011, from 859 cases 
per 100,000 inhabitants [95% CI: 798-920] to 9 cases per 100,000 inhabitants [95% CI: 4-14]. 
A change in the age distribution is significant with an increase of Relative Illness Ratio (RIR) 
for patients over 20 years. Since 2000, vaccine status has also changed, and the majority of 
recent mumps cases occur among previously vaccinated patients. The average annual 
hospitalisation rate is 3.2 per 1 million inhabitants. Mumps was identified as the initial cause 
of death in 1 case every 5 years. This study estimates the burden of mumps disease in France. 
Keywords  
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1. Introduction  
 Although mumps is usually mild in children, the risk of complications increases in 
adults (including encephalitis, orchitis or pancreatitis) (1). Sequelae may also be seen such as 
deafness or testicular atrophy (2). On December 2007, 114 of 193 (57%) World Health 
Organization (WHO) member states began to include vaccination against mumps in their 
national immunisation programs (3). This large-scale vaccination has resulted in a sharp drop 
of the mumps incidence rate within a few years (4). In France, vaccination against mumps 
was recommended in 1986 as a single dose, and a second dose has been added in 1996. 
In 2002-2003, French vaccination coverage for mumps in the last year of kindergarten 
was 92.6% for the first dose, and 24.4% for the second dose (5). Mathematical models 
indicate, that  a vaccination rate of 85 to 90%  would be required to prevent virus circulation 
(6). Insufficient coverage, limiting the circulation of the mumps virus in the population 
without eradicating it entirely and lowering exposure during childhood, might lead to a shift 
in the incidence of this disease to older age classes (4, 7-9) for whom complications are more 
important (10, 11). Indeed, several recent outbreaks have primarily affected the 15-24 years 
old age group (12-14) with a higher complication rate among patients over 15 years old (15). 
The persistent occurrences of mumps cases, whilst the epidemiology of the disease is 
also changing (4, 7-9), requires careful monitoring to assess the burden of mumps disease and 
to adapt effective public health measures. Unlike the USA (16), the United Kingdom (17) or 
Greece (7), mumps is not a notifiable disease in France, and the monitoring is performed since 
1985 by general practitioners (GPs) of the French GPs Sentinelles network. This network of 
research and surveillance, created in 1984, is incorporated into a mixed research unit of 
National Institute of Health and Medical Research (INSERM) and Pierre and Marie Curie 
University (UPMC) (18, 19). The network is developed in collaboration with the National 
Institute for Public Health Surveillance (InVS). This study presents the analysis of data 
collected by this network between 1986 and 2011. This work is supplemented by 
hospitalisations and deaths national data analysis sourced from the national databases of 
Program Medicalisation of Information Systems (PMSI) and French epidemiological center of 
medical causes of death (CépiDc). The disease’s incidence in primary care, as well as 
hospitalisation and mortality are considered to assess the burden of mumps disease in France. 
2. Materials and methods 
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2.1 Source of data 
2.1.1 Mumps cases in general practice 
On January 1st, 2012, there were approximately 1313 voluntary and unpaid general 
practitioners (GPs) (20) in the French GPs Sentinelles network, equivalent to 2.2% of all GPs 
in France (60,963 GPs at December 31, 2010 according to the French National fund of health 
insurance for employees (CNAMTS) (21)). Mumps Cases are reported every week in a 
standardised and automated manner by 359 of these GPs. The characteristics of the GPs of the 
Sentinelles network are comparable to those of all French GPs regarding regional distribution, 
proportion in rural practice, type of practice and distribution of main clinical skills (22). A 
case of mumps is defined either by a unilateral or bilateral parotid swelling, painful and 
developed recently often associated with testicular, pancreatic, brain damage, or meningitis, 
or - in the absence of parotitis - by orchitis, meningitis or pancreatitis with a mumps 
laboratory confirmation. For each case, GPs have to report age, sex and vaccine status. If the 
patient has been vaccinated, the date of vaccination as well as the number of doses received 
(item collected since 2009) and the source of this information (patient’s immunization registry 
or statement from patients or parents) is required. An exposure to another case of mumps 
disease during the 21 days before illness, and a complication (orchitis, meningitis, 
pancreatitis, other) are collected since 1997. Laboratory confirmation (presence of IgM and / 
or multiplication of the IgG by a factor of 4) is collected since 2011. Data recovered for 
mumps are collected from January 1, 1986 to December 31, 2011. 
2.1.2. Mumps hospitalisations  
Hospitalisation data are collected by reviewing all hospital discharge reports 
containing a mumps code from January 1, 2004 to December 31, 2010 (last available data at 
the time of writing this paper). The data is obtained through the PMSI Data Processing Centre 
(23), which is a national register of all discharges from all short-stay to acute-care stays. It 
collects data described by the physicians who took care of the patients during the 
hospitalisation. Diagnoses are coded using the International Classification of Diseases, Tenth 
Revision (ICD-10), either as primary or associated diagnosis. For this study we select all 
hospital discharge reports between January 1, 2004 and December 31, 2010. Mumps 
hospitalisations were defined as an hospital discharge report with a primary or an associated 
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mumps diagnosis specific code (B26 *: B260 - B261 - B262 - B263 - B268 - B269, 
respectively encoding mumps orchitis, mumps meningitis, mumps encephalitis, and mumps 
(24)). Information on age, sex, and duration of hospitalisation was also obtained from the 
hospital discharge reports. 
2.1.3. Mumps mortality  
Mumps mortality is assessed through the French National Mortality Database 
(INSERM CépiDc) for deaths between January 1, 2000, and December 31, 2009 (the last 
available data at the time of writing this paper) (25). Mumps deaths are defined as any death 
certificate with an International Classification of Disease code for mumps and its 
complications (ICD-10 codes B26 *) as underlying cause in accordance with WHO rules. 
Information on age and sex is also obtained. 
2.2. Analysis 
To obtain the yearly national incidence rate, the mean number of cases per Sentinelles 
GP (standardised according to their participation and their geographical distribution) is 
multiplied by the total number of GPs in France and the result is then divided by the 
population of that year, using the French population included in national censuses as a 
reference (21). These estimates are based on one assumption: the Sentinelles GPs are a 
random sample representative of all French doctors (26). Age-specific incidences rates are 
also estimated for the following age groups: <4 years, 5-9yrs, 10-14years, 15-19, 20-24, 25-29 
and> 30 years, comparable to age structure used by the European Centre for Disease 
prevention and Control (ECDC) for European Health Surveillance (8). Calculation of the 95% 
confidence interval (IC 95%) is based on the hypothesis that the number of reported cases 
followed a Poisson distribution. In order to develop a better understanding with regards to the 
burden of mumps disease in a given age group, the Relative Illness Ratio (RIR) is also 
calculated as the ratio between the percentage of cases in a given age group and the 
percentage of the general population belonging to the same age (formula below). The latter of 
these ratios is estimated for each year by the French National Institute of Statistics and 
economic studies (INSEE) (27). 
RIR = (Ci / Ci Σ) / (Ni / Ni Σ) 
Ci: number of mumps cases for a given age 
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 Σ Ci: sum of mumps cases all age groups combined 
Ni: population for a given age, 
Ni Σ: sum of all populations of different ages (30) 
Hospitalisation and mortality rates are calculated in a similar way. 
3. Results 
3.1. In general practice 
Between the first week of 1986 and the last week of 2011, 6,141 mumps cases were 
reported by GPs of the French Sentinelles network, including 5,597 cases (91.1%) 
individually described. During the entire study period, the estimated yearly incidence 
decreased from 475,671 cases (95% CI: 441,867-509,475) in 1986, which corresponds to 859 
cases per 100,000 inhabitants [95%: 798-920], to 5,841 cases (95% CI: 2,817-8,865) in 2011, 
which corresponds to 9 cases per 100,000 inhabitants [95% CI, 4-14]. An initial sharp 
decrease was observed in 1988, followed by a second in 1993. Between 1997 and 2011, a low 
but continuous decrease was observed (Figure 1 and Table 1). 
Males represented 54.6% of mumps cases (3,010 cases) without significant 
modification of the sex ratio during the study period. The median age was 6 years [4-10] and 
the mean age 9.4 years old. The median age increased from 5 years old in 1986 to 16.5 years 
old in 2011, such that the mean age increased from 8.2 years old to 21.9 years old. Whilst 
between 1986 and 1998 incidence rates declined steadily for all age groups, after the year 
1998 they ceased to decline for patients under 20 years old. However, the incidence rate for 
patients over 20 years old did not change, from a rate of incidence of 10 per 100,000 in 1998 
to 11 per 100,000 in 2011 for the 20-24 year old patients. Over the entire monitoring period, 
the trend observed for RIR by age group was a decrease for patients under 10 years old, stable 
for 10-14 years old, and rising for patients over15 years old (Figure 2). 
The overall percentage of reported mumps cases vaccinated was 18.3% (n=945 of 
5,171 cases described for this item). Since 2009, and the need for specifications regarding the 
number of vaccine doses received, 52.7% cases of mumps received two doses of vaccine 
(n=19 of 36 cases described in this item). The distribution of cases according to the vaccine 
status changed between 1986 and 2011, ranging from a majority of cases among unvaccinated 
patients (735 cases were not vaccinated in 1986, corresponding to 98.1% of cases for that 
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year) to a majority of cases among previously vaccinated patients since 2000 (11 cases are 
vaccinated in 2011, corresponding to 68.8% of cases) (Figure 3). Vaccine status was 
determined by GPs according to the patient’s immunization registry in 72.6% of cases, and 
according to statements from patients or their relatives in 27.4% of cases. An exposure was 
reported in 26.6% of cases (n=72 of 271 cases described in this item). The place of exposure 
was specified for 25% of these cases (n=68): most of them were exposed at school (30.9%, 
n=21). 
Since 1997, after which time data collection begins, 18.5% of declared mumps cases 
presented a complication according to the GP (n=57 of 308 cases described in this item). But 
only 8 of them were described (4 orchitis, 1 meningitis, 1 pancreatitis, and 2 pharyngitis-
bronchitis). The proportion of mumps cases described with a complication decreased 
significantly, ranging from 42.6% in 1998 cases (20/47) to 0% in 2011 (0/20). Complicated 
cases were seen predominantly in 10-14 year old age groups (17 cases corresponding to 
29.8% of complicated mumps). 
From January 1, 2011, GPs have the opportunity to specify whether or not their 
clinical diagnosis was completed by a laboratory confirmation. Of the 22 reported mumps 
cases in 2011, two cases had a laboratory confirmation while 15 were not laboratory 
investigated. In 5 cases this information was not specified by the GP. 
3.2. Mumps hospitalisations 
Over the seven-year study period, 1,377 hospitalisations with a primary or associated 
mumps diagnosis, corresponding to 1331 patients, were identified. These cases included 597 
hospitalisations / 592 patients with a primary mumps diagnosis. Among these patients with a 
primary mumps diagnosis, 99.2% (n = 587) were hospitalised once for this reason, and 0.8% 
(n=5) were hospitalised twice for mumps orchitis. A mean of 85.3 hospitalisations with a 
primary mumps diagnosis was identified each year, corresponding to 84.6 patients per year. 
The average rate of hospitalisation for mumps per year was 1.4 per 1 million inhabitants for 
the period spanning 2004-2010. The annual number of hospitalisations increased from 75 to 
111 between 2004 and 2010 (Table 2). 
Males represented 55% of hospitalised cases for mumps (n=325). Patients older than 
30 years represented 37% of patients (n=220) hospitalised for mumps (Figure 4). The reasons 
of hospitalisation were mumps parotitis for 78.6% of cases (n = 465), orchitis for 9.3% of 
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cases (n=55), meningitis for 3.2% of cases (n= 19), pancreatitis for 2% of cases (n=12) and 
encephalitis for 0.8% of cases (n=5). 10% of patients (n=59) were hospitalised for mumps 
parotitis described as "complicated" but without further explanation. The average length of 
stay was 2 days per hospitalisation (median 6 days ± 0 days), with the same holding for the 
different complications. 
3.3. Mumps mortality 
During the period of 2000–2009, mumps as the initial or associated diagnosis was 
coded in 82 death certificates. After analysis of the death certificates, mumps was selected as 
the initial cause of death in 2 cases (2.4%), and as an associated cause in 3 cases (3.7%). In 
total, 33 cases of "bacterial parotitis" (40.2%) and 44 cases of unspecified "infectious 
parotitis" (53.6%) were excluded. Selected death certificates concerned 3 men and 2 women. 
The median age was 67 years (50 years - 84 years), and the mean age 71.8 years. For both 
certificates for which mumps was selected as the initial cause of death, the associated causes 
were “cardiopulmonary arrest” for one and “encephalopathy” for the second. 
4. Discussion 
This work provides, through public national databases, an estimate of the morbidity 
and mortality for mumps in France since 1986. The main results detail the fall in the incidence 
of mumps, as well as the change in the age structure and in the vaccine status of patients. 
 The decrease of mumps incidence in France immediately follows the 1986 onset of 
mumps vaccination in France. Identical decreases in incidence rates are found in countries 
recommending vaccination against mumps: ECDC describes a fall of the mean incidence rate 
from 62 per 100,000 in 1995 (28) to 3.2 per 100,000 in 2009 in 27 European Union countries 
(7). In U.S.A., mumps incidence decreased from 90 per 100,000 in 1967 to 0.7 per 100,000 in 
1993 (29). Finland did not report any indigenous cases of mumps, 16 years after the 
establishment in 1982 of a two-dose vaccination schedule against mumps (30). However in 
France, mumps cases are diagnosed and hospitalised each year, as shown in this manuscript. 
Mumps vaccine coverage have to be increased, especially for the second dose (5). GPs, who 
are in favour of this vaccination for 96.8% of them (31), have a major role on this point. 
The number of mumps cases in adults is not increasing, but an increase of the median 
and mean ages is observed. An increase of the Relative Illness Ratio for patients over 20 years 
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old is confirmed, such as that observed in outbreaks which occur in other countries. In 
Ireland, Gee & Al describe epidemics which occur between 2004 and 2008 as primarily 
affecting the 15-19 and 20-24 years old age groups (14). In the USA in 2006, Dayan & Al 
also find an incidence rate of 31.1 cases per 100,000 among 18-24 years old against 8.4 per 
100,000 for all other age groups together (13). Shmid & Al report  that in Austria, the age 
group of 21-25 years old is the most affected in 2006 (42% of cases) (32). This shift in age 
groups affected can be explained by an insufficient level of the mumps herd immunity for 
unvaccinated persons, in a context of a low circulation of mumps virus (33). 
As expected, the majority of recent mumps cases occur among previously vaccinated 
patients. Such results have been published concerning some recent outbreaks in western 
countries: during 2006 in the United States, 77% to 97% of mumps cases were previously 
vaccinated with two doses (1), such as 69% of cases during Canadian outbreaks in 2005(4). 
This change is expected because of vaccination rate increases, and does not mean that 
vaccination policies have failed. However, it suggests that mumps vaccination clinical 
efficiency measured during outbreaks seems less effective than serological efficiency 
measured during clinical trials. For Jeryl Lynn strain, the  serological efficiency is estimated 
to 95% (34), against 64 to 66% for clinical efficiency with a single dose, and 83 to 88% with 
two doses (35). Moreover, vaccination immunity may last for a shorter period of time than 
expected (36). This issue should be better analysed, as in a recent article on seroepidemiology 
of mumps in Europe, which presents ways to improve the mumps vaccination schedule (37). 
This work also confirms the mild aspect of mumps. If 18.5% of cases seen in general 
practice present a complication, only a few of these complications are described by the GPs, 
suggesting a possible overestimation of this number. Moreover, according to PMSI data, 3% 
of mumps cases only are hospitalised. This result corroborates international findings which 
estimate that, among mumps cases, 4% are hospitalised (8). Patients hospitalised for mumps 
are mostly over 30 years of age, following the trend of hospitalised cases in Europe (8). 
Finally, it is important to note that only 2 deaths are attributable to mumps in 10 years of 
surveillance in France. There are no published international data on mumps mortality. Most of 
hospitalised mumps cases in Europe corresponding to 23% of cases are between 20 and 24 
years of age in 2009 (8). 
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This study has both strengths and limitations. GPs from the GPs Sentinelles network 
appear representative of all French GPs, given their demographic characteristics (22, 26) and 
practices (work in progress at Inserm Unit in collaboration with CNAMTS). The incidence of 
mumps cases could be underestimated, due to asymptomatic patients who are not identified 
(approximately 30% to 40% of cases according to Hviid & Al (2), and may be more among 
previously vaccinated patients (38)). There are several limitations associated with using 
hospitalisation and death records, as inadvertent omissions and coding errors. It is important 
to notice that B26 code includes all infectious parotitis (24), and that the death certificates 
analysis shows that the main part of B269 codes are used for bacterial parotidis and not for 
mumps parotidis. These potential errors, induced by an imprecise ICD-10 definition, may 
have happened also for hospitalisations. Conversely, mumps incidence could be 
overestimated; because of the laboratory confirmation is not required to report a case. 
Davidkin & Al show that 831 mumps laboratory tests are negative on 848 clinical mumps 
cases during a study led in Finland between 1983 and 1998. Another viral etiology is found in 
14% of cases (EBV, parainfluenza virus types 1 and 3, enterovirus, adenovirus, parvovirus 
B19, HHV-6) (39).  
In conclusion the risk of clustered cases of mumps in France seems to be a 
combination of several factors: an insufficient vaccination rate for the second dose, the 
assumption of a loss of immunity over time even after two vaccine doses, and the existence of 
cohorts of young adults not enough vaccinated in the context of a significant reduction of the 
virus circulation. According to these results, the question regarding the reality of mumps 
estimation based on a clinical cases declaration should be discussed. As a monitoring strategy, 
biological testing included in mumps case definition seems necessary in order to establish 
whether or not the mumps virus remains in circulation. 
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Figure 1: Annual mumps incidence rate per 100,000 inhabitants in France, and confidence 
interval 95%, from 1986 to 2011. 
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Figure 2: Relative Illness Ratio of mumps cases according to age between 1986 and 2011 in 
France 
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Figure 3: Percentage of mumps cases seen in consultation of general practice in France 
according to vaccine status between 1986 and 2011 
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Figure 4: Number of hospitalised cases for mumps in France according to age between 2004 
and 2010 
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Table 1: Annual mumps incidence rate per 100,000 inhabitants in France, and 
confidence interval 95%, according to age groups between 1986 and 2011. 
 
Years 
All age 
together 
0-4 years 
old 
5-9 years 
old 
10-14 years 
old 
15-19 
years 
old 
20-24 
years 
old 
25-29 
years old 
>30 years 
old 
1986 
859 
[798-920] 
3762 
[3345-4179] 
4810 
[4147-5473] 
831 
[635-1027] 
177 
[92-262] 
169 
[84-254] 
157 
[72-241] 
60 
[30-90] 
1987 
959 
[901-
1018] 
4488 
[4028-4947] 
5076 
[4553-5598] 
1129 
[866-1392] 
220 
[95-345] 
100 
[46-154] 
200 
[99-300] 
65 
[33-97] 
1988 
235 
[514-256] 
1028 
[855-1201] 
1347 
[1161-1533] 
435 
[320-550] 
104 
[52-156] 
40 
[13-68] 
84 
[36-131] 
27 
[9-45] 
1989 
132 
[113-150] 
849 
[661-1037] 
633 
[472-794] 
226 
[149-303] 
74 
[24-124] 
36 
[3-69] 
14 
[0-33] 
4 
[0-10] 
1990 
190 
[160-220] 
893 
[600-1187] 
1313 
[1032-1594] 
157 
[74-240] 
43 
[1-84] 
49 
[0-99] 
82 
[2-162] 
12 
[0-26] 
1991 
221 
[192-250] 
823 
[603-1043] 
1497 
[1200-1794] 
454 
[314-594] 
106 
[37-175] 
36 
[0-74] 
91 
[5-176] 
21 
[7-37] 
1992 
246 
[223-270] 
892 
[712-1073] 
1598 
[1368-1827] 
596 
[464-728] 
116 
[55-177] 
71 
[25-116] 
66 
[22-110] 
25 
[7-42] 
1993 
156 
[140-172 
487 
[381-594] 
1009 
[852-1167] 
453 
[348-558] 
89 
[43-135] 
51 
[18-84] 
46 
[12-80] 
14 
[4-25] 
1994 
94 
[80-107] 
321 
[216-425] 
479 
[365-594] 
323 
[228-417] 
30 
[6-53] 
14 
[0-28] 
39 
[7-70] 
13 
[3-24] 
1995 
86 
[74-99] 
314 
[213-416] 
401 
|301-501] 
331 
[239-424] 
42 
[3-82] 
27 
[2-51] 
9 
[0-20] 
12 
[1-24] 
1996 
89 
[74-103] 
311 
[209-414] 
499 
[344-653] 
284 
[192-376] 
61 
[23-100] 
10 
[0-25] 
18 
[0-38] 
9 
[2-16] 
1997 
68 
[55-82] 
207 
[119-295] 
335 
[216-455] 
200 
[116-285] 
76 
[10-141] 
37 
[0-76] 
19 
[0-48] 
9 
[0-20] 
1998 
44 
[33-54] 
115 
[37-193] 
238 
[145-331] 
89 
[37-142] 
36 
[6-66] 
10 
[0-29] 
26 
[0-52] 
8 
[0-19] 
1999 
38 
[27-50] 
223 
[108-338] 
64 
[2-126] 
86 
[17-156] 
28 
[0-62] 
24 
[0-59] 
0 
8 
[0-19] 
2000 
30 
[17-43] 
50 
[1-99] 
129 
[2-257] 
78 
[2-153] 
13 
[0-38] 
49 
[4-94] 
21 
[0-62] 
1 
[0-3] 
2001 
20 
[11-29] 
90 
[19-162] 
95 
[0-191] 
20 
[0-47] 
37 
[0-82] 
11 
[0-33] 
10 
[0-31] 
2 
[0-7] 
2002 
19 
[9-29] 
19 
[0-55] 
55 
[1-110] 
15 
[0-35] 
39 
[0-97] 
0 
25 
[0-60] 
0 
2003 
20 
[9-32] 
95 
[1-189] 
70 
[0-149] 
33 
[0-81] 
12 
[0-35] 
0 
11 
[0-33] 
46 
[0-115] 
2004 
21 
[13-30] 
57 
[0-115] 
101 
[27-175] 
56 
[0-116] 
12 
[0-35] 
10 
[0-30] 
12 
[0-37] 
6 
[0-15] 
2005 
28 
[11-45] 
51 
[|0-109] 
242 
[0-489] 
57 
[0-141] 
0 
 
0 0 
7 
[0-15] 
2006 
12 
[6-18] 
64 
[4-125] 
83 
[20-145] 
11 
[0-33] 
0 
6 
[0-19] 
0 
13 
[0-32] 
2007 
13 
[5-21] 
158 
[36-281] 
5 
[0-15] 
0 
 
0 
1 
[0-2] 
5 
[0-16] 
3 
[0-9] 
2008 
8 
[4-12] 
6 
[0-18] 
34 
[0-69] 
8 
[0-24] 
15 
[0-36] 
0 0 
3 
[0-6] 
2009 
18 
[11-24] 
60 
[1-118] 
45 
[5-84] 
38 
[6-71] 
46 
[0-94] 
25 
[0-55] 
28 
[0-59] 
3 
[0-8] 
2010 
10 
[5-14] 
46 
[8-83] 
22 
[0-50] 
NA 
17 
[0-36] 
19 
[0-46] 
0 
5 
[0-12] 
2011 
9 
[4-14] 
26 
[0-58] 
26 
[0-57] 
20 
[0-45] 
11 
[0-26] 
11 
[0-32] 
5 
[0-14] 
4 
[0-11] 
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Table 2 : Number of hospitalised cases and number of hospitalisations* per year in France 
between 2004 and 2010, according primary or associated mumps diagnosis  
 
 
Primary mumps diagnosis  
+ 
Associated mumps diagnosis 
Primary mumps diagnosis  
only 
Year 
Number of 
hospitalised cases  
(n) 
Number of 
hospitalisations*  
(n) 
Number of 
hospitalised cases  
(n) 
Number of 
hospitalisations*  
(n) 
2004 199 206 73 75 
2005 190 199 73 73 
2006 155 163 80 80 
2007 170 177 75 78 
2008 185 187 83 83 
2009 211 216 97 97 
2010 221 229 111 111 
* Some cases have been hospitalised more than one time. 
 
